Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody

Abstract

Invasion of erythrocytes by Plasmodial merozoites is a composite process involving the interplay of several proteins. Among them, the Plasmodium falciparum Cysteine-Rich Protective Antigen (PfCyRPA) is a crucial component of a ternary complex, including Reticulocyte binding-like Homologous protein 5 (PfRH5) and the RH5-interacting protein (PfRipr), essential for erythrocyte invasion. Here we present the crystal structure of PfCyRPA and of its complex with the antigen-binding fragment of a parasite growth inhibitory antibody. While PfCyRPA adopts a 6-bladed β-propeller structure with similarity to the classic sialidase fold, it possesses no sialidase activity, indicating that it fulfills a non-enzymatic function. Characterization of the epitope recognized by protective antibodies will facilitate design of peptidomimetics that focus vaccine responses on protective epitopes. Both in vitro and in vivo anti-PfCyRPA and anti-PfRH5 antibodies showed more potent parasite growth inhibitory activity in combination than on their own, supporting a combined delivery of PfCyRPA and PfRH5 in vaccines.

Data availability

The following data sets were generated
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of Fab c12
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZI).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of Fab c12
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZL).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of Fab c12
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZJ).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of PfCyRPA
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZN).
    1. Favuzza A
    2. Pluschke G
    3. Rudolph MG
    (2017) Crystal Structure of PfCyRPA
    Publicly available at the RCSB Protein Data Bank (accession no: 5EZO).
The following previously published data sets were used

Article and author information

Author details

  1. Paola Favuzza

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0002-1394-927X
  2. Elena Guffart

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  3. Marco Tamborrini

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  4. Bianca Scherer

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  5. Anita M Dreyer

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  6. Arne C Rufer

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  7. Johannes Erny

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  8. Joerg Hoernschemeyer

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  9. Ralf Thoma

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  10. Georg Schmid

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  11. Bernard Gsell

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  12. Araceli Lamelas

    Red de Estudios Moleculares Avanzados, Instituto de Ecología A.C., Xalapa, Mexico
    Competing interests
    The authors declare that no competing interests exist.
  13. Joerg Benz

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  14. Catherine Joseph

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  15. Hugues Matile

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    Competing interests
    The authors declare that no competing interests exist.
  16. Gerd Pluschke

    Medical Parasitology and Infection Biology Department, Swiss Tropical and Public Health Institute, Basel, Switzerland
    For correspondence
    Gerd.Pluschke@unibas.ch
    Competing interests
    The authors declare that no competing interests exist.
    ORCID icon "This ORCID iD identifies the author of this article:" 0000-0003-1957-2925
  17. Markus G Rudolph

    Roche Pharmaceutical Research and Early Development, Roche Innovation Center Basel, Basel, Switzerland
    For correspondence
    markus.rudolph@roche.com
    Competing interests
    The authors declare that no competing interests exist.

Funding

Uniscientia Stiftung

  • Gerd Pluschke

The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.

Ethics

Animal experimentation: All procedures involving living animals were performed in strict accordance with the Rules and Regulations for the Protection of Animal Rights (Tierschutzverordnung) of the Swiss Federal Food Safety and Veterinary Office. The protocol was granted ethical approval by the Veterinary Office of the county of Basel-Stadt, Switzerland (Permit Numbers: 2375 and 2303).

Copyright

© 2017, Favuzza et al.

This article is distributed under the terms of the Creative Commons Attribution License permitting unrestricted use and redistribution provided that the original author and source are credited.

Metrics

  • 3,148
    views
  • 634
    downloads
  • 57
    citations

Views, downloads and citations are aggregated across all versions of this paper published by eLife.

Download links

A two-part list of links to download the article, or parts of the article, in various formats.

Downloads (link to download the article as PDF)

Open citations (links to open the citations from this article in various online reference manager services)

Cite this article (links to download the citations from this article in formats compatible with various reference manager tools)

  1. Paola Favuzza
  2. Elena Guffart
  3. Marco Tamborrini
  4. Bianca Scherer
  5. Anita M Dreyer
  6. Arne C Rufer
  7. Johannes Erny
  8. Joerg Hoernschemeyer
  9. Ralf Thoma
  10. Georg Schmid
  11. Bernard Gsell
  12. Araceli Lamelas
  13. Joerg Benz
  14. Catherine Joseph
  15. Hugues Matile
  16. Gerd Pluschke
  17. Markus G Rudolph
(2017)
Structure of the malaria vaccine candidate antigen CyRPA and its complex with a parasite invasion inhibitory antibody
eLife 6:e20383.
https://doi.org/10.7554/eLife.20383

Share this article

https://doi.org/10.7554/eLife.20383

Further reading

    1. Structural Biology and Molecular Biophysics
    Erik Henze, Russell N Burkhardt ... Toshimitsu Kawate
    Research Article

    In addition to its role as cellular energy currency, adenosine triphosphate (ATP) serves as an extracellular messenger that mediates diverse cell-to-cell communication. Compelling evidence supports that ATP is released from cells through pannexins, a family of membrane proteins that form heptameric large-pore channels. However, the activation mechanisms that trigger ATP release by pannexins remain poorly understood. Here, we discover lysophospholipids as endogenous pannexin activators, using activity-guided fractionation of mouse tissue extracts combined with untargeted metabolomics and electrophysiology. We show that lysophospholipids directly and reversibly activate pannexins in the absence of other proteins. Secretomics experiments reveal that lysophospholipid-activated pannexin 1 leads to the release of not only ATP but also other signaling metabolites, such as 5’-methylthioadenosine, which is important for immunomodulation. We also demonstrate that lysophospholipids activate endogenous pannexin 1 in human monocytes, leading to the release of IL-1β through inflammasome activation. Our results provide a connection between lipid metabolism and purinergic signaling, both of which play major roles in immune responses.

    1. Structural Biology and Molecular Biophysics
    Mia L Abramsson, Robin A Corey ... Michael Landreh
    Research Article

    Integral membrane proteins carry out essential functions in the cell, and their activities are often modulated by specific protein-lipid interactions in the membrane. Here, we elucidate the intricate role of cardiolipin (CDL), a regulatory lipid, as a stabilizer of membrane proteins and their complexes. Using the in silico-designed model protein TMHC4_R (ROCKET) as a scaffold, we employ a combination of molecular dynamics simulations and native mass spectrometry to explore the protein features that facilitate preferential lipid interactions and mediate stabilization. We find that the spatial arrangement of positively charged residues as well as local conformational flexibility are factors that distinguish stabilizing from non-stabilizing CDL interactions. However, we also find that even in this controlled, artificial system, a clear-cut distinction between binding and stabilization is difficult to attain, revealing that overlapping lipid contacts can partially compensate for the effects of binding site mutations. Extending our insights to naturally occurring proteins, we identify a stabilizing CDL site within the E. coli rhomboid intramembrane protease GlpG and uncover its regulatory influence on enzyme substrate preference. In this work, we establish a framework for engineering functional lipid interactions, paving the way for the design of proteins with membrane-specific properties or functions.